MSB 1.34% $1.51 mesoblast limited

Cell Therapy News/Articles, page-16024

  1. 7,698 Posts.
    lightbulb Created with Sketch. 6966
    Yes, yes, I know, placenta cells, but the overwhelming tide of clinical evidence towards successful MOA by stem cells in congenital heart disease keeps building in MSB's favour:

    https://healthnews.com/news/stem-cells-from-placenta-save-child-with-congenital-heart-disease/

    the FDA has given the okay to stem cells to address blood disorders, as I recently highlighted with Omidubicel. The regulatory and clinical acceptance of stem cells as formal treatments, finally evolving. We are on the threshold and its hard not to get a little excited for patients and science, beyond any financial gain.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.